abstract |
Compounds of Formula (I) or (Ia), pharmaceutically acceptable salts, stereoisomers, tautomers, solvates or prodrugs, and their use as HPK1 inhibitors are described herein, and also described are methods for preparing the compounds, and methods of treating HPK1-dependent diseases or disorders, such as cancer. |